Recruiting

HIIT

Sponsor:

Université de Sherbrooke

Code:

NCT04986345

Conditions

Diabetes Mellitus, Type 2

Eligibility Criteria

Sex: Female

Age: 60 - 70+

Healthy Volunteers: Not accepted

Interventions

High-intensity interval training (HIIT)-4

High-intensity interval training (HIIT)-10

Rest

Study Details

Brief summary:

Type 2 diabetes (T2D) prevalence has steadily been rising in the past decades and its complications, including cardiovascular diseases (CVD), are a major public health concern.

To lower CVD risk and to maintain an adequate glycemic control, Diabetes Canada recommends aerobic exercise of high-intensity interval training (HIIT). The leading hypothesis of this study is that longer intervals will favor an anti-inflammatory immune state, and that and that it will be correlated with reduced arterial stiffness and blood pressure.

Conditions

Diabetes Mellitus, Type 2

Study ID

NCT04986345

Start date

Oct 4, 2021

Status verified date

Mar, 2023

Completion date

Aug 31, 2023

Anticipated

Primary completion date

May 15, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 60 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • With a diagnostic for type 2 diabetes
  • Arterial hypertension (controlled at rest)
  • Low or no alcohol consumption (≤ 7 alcoholic beverages/week)
  • Non-smoking
  • Physically active ( > 60 minutes of structured and scheduled physical activity/week for the previous 3 months)

Exclusion Criteria:

  • Insulin therapy
  • Use of beta blockers
  • Unstable medication in the past 6 months
  • Stroke in the past 6 months, or with consequences limiting physical activity practice
  • Coronary disease without revascularization, or peripheral artery disease
  • Neuropathy, retinopathy of nephropathy diagnostics
  • Orthopedic limitations, or medical counter-indication for physical activity practice
  • Surgery scheduled during the study period

Study Design

Enrollment

15 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Rest, HIIT-4, HIIT-10

Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.

This arm's sequence of intervention is : 1-Rest; 2- HIIT-4 and 3- HIIT-10.

experimental: Rest, HIIT-10, HIIT-4

Both arms start with the rest condition and the order of the two other conditions (HIIT-4 and HIIT-10) is determined at random.

This arm's sequence of intervention is : 1- Rest; 2- HIIT-10 and 3- HIIT-4.

Interventions

High-intensity interval training (HIIT)-4

4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.

High-intensity interval training (HIIT)-10

10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.

Rest

Participants are to stay seated for 30 minutes while reading or watching television.

Primary outcome measure

  • Change in ambulatory systolic and diastolic blood pressure [ Time Frame: During 24 hours after the three experimental conditions (Rest, HIIT-4 and HIIT-10) ]

Central Contacts and Locations

Central contacts

Eléonor Riesco, PhD

1-819-821-8000e.riesco@usherbrooke.ca

Locations

Centre de recherche sur le vieillissement

Recruiting

Sherbrooke, Quebec, Canada, J1H 4C4

Contacts

Eléonor Riesco, PhD

1-819-821-8000eleonore.riesco@usherbrooke.ca

Principal Investigator:

Eléonor Riesco, PhD

More Information

Sponsor

Université de Sherbrooke

Last update posted

Mar 30, 2023

Last verified

Mar, 2023

Keywords

  • Type 2 diabetes
  • Ambulatory blood pressure
  • Continous glucose monitoring
  • High-intensity interval training
  • Proteomics
  • Monocytes
  • Inflammation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Université de Sherbrooke on 2023-03-30.